source
- Ivonescimab cuts death risk by one-third in Chinese lung cancer trial, adds four-month survivalA trial in China evaluated ivonescimab combined with chemotherapy in patients newly diagnosed with advanced non-small cell lung cancer. The study was presented at the American Society of Clinical O…
- Personalized vaccines show promise in extending survival for some brain cancer patients, Dana-Farber study findsPersonalized cancer vaccines are being investigated as a way to make aggressive brain tumors more responsive to immunotherapy, according to new research from the Dana-Farber Cancer Institute. The…